Fusion Proteins Or Polypeptides Patents (Class 435/69.7)
  • Patent number: 10653752
    Abstract: Methods and compositions for the use of long-acting hematopoietic factor protein analogs for accelerating hematopoietic recovery in subjects who have been or will be exposed to radiation are disclosed.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: May 19, 2020
    Assignee: Bolder Bio Technology, Inc.
    Inventors: George N. Cox, Christie M. Orschell
  • Patent number: 10548921
    Abstract: Disclosed are compositions and methods related to rendering ineffective Th1 T cells resistant to the inhibitory cytokine milieu present in a cancer microenvironment. Tumor-specific T cells are modified to employ a chimeric receptor that binds inhibitory/suppressive cytokines and converts their intracellular consequences to a Th1 immunostimulatory/activating signal. The T cells employ a chimeric antigen receptor having exodomains for IL10, IL13 and/or IL4 fused with the signal transducing endodomains for IL2 and/or IL7.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: February 4, 2020
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: Ann Marie Leen, Juan F. Vera
  • Patent number: 10544198
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: January 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Xiaoting Wang, Ganesh A. Kolumam, Wyne P. Lee
  • Patent number: 10464979
    Abstract: Disclosed herein are FGF23 c-tail fusion proteins, pharmaceutical compositions comprising the FGF23 c-tail fusion proteins, and methods of treatment using the FGF23 c-tail fusion proteins. This application discloses fusion proteins comprising a FGF-23 c-tail protein fused to a heterologous amino acid sequence, wherein said fusion protein modulates serum phosphate levels but does not substantially modulate serum 1, 25 VitD levels. In some embodiments, the FGF-23 c-tail protein is fused to the heterologous amino acid sequence via a linker. This invention also encompasses vectors comprising the nucleic acids disclosed herein, and a host cell comprising the vector or polynucleotides encoding the proteins of the invention.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: November 5, 2019
    Assignees: New York University, Pfizer Inc.
    Inventors: Moosa Mohammadi, Regina Goetz, Jeanne Sue Magram, Kristen Leigh Johnson
  • Patent number: 10435451
    Abstract: The present invention provides a fusion protein comprising a latency associated peptide (LAP), a pharmaceutically active agent and an amino acid sequence comprising a dimerization domain, wherein the LAP and the pharmaceutically active agent are connected by an amino acid sequence comprising a proteolytic cleavage site. Also provided are nucleic acids enclosing such fusion proteins, process for their preparation, pharmaceutical compositions, kits and uses thereof in medicine.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: October 8, 2019
    Assignee: Stealthyx Therapeutics Limited
    Inventors: Yuti Chernajovsky, Lisa Mullen, Gillian Adams, David James Gould, Hawzheen Muhammad
  • Patent number: 10414729
    Abstract: Dynamic nuclear polarization (DNP) agents are provided for DNP nuclear magnetic resonance of analytes. The DNP agents can have the structure A-X-L-R, where A is none or an amphiphilic group; X is a coupling group capable of site-specific binding with the analyte or, when A is an amphiphilic group, capable of site-specific binding with the amphiphilic group; L is a bond or a linker group; and R is a poly-radical group. The poly-radical can be a di-radical, a tri-radical, a tetra-radical, or a combination thereof. Methods of NMR measurement of an analyte comprising an NMR-detectable nucleus are provided. The methods can include the steps of providing a frozen sample containing the analyte and a DNP agent; applying radiation having a frequency that excites electron spin transitions in the DNP agent at an intensity to polarize the NMR-detectable nucleus; and detecting a signal from nuclear spin transitions in the NMR-detectable nucleus.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: September 17, 2019
    Assignee: NORTH CAROLINA STATE UNIVERSITY
    Inventors: Alexej I. Smirnov, Maxim Anatolyevich Voynov
  • Patent number: 10370424
    Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: August 6, 2019
    Assignee: Wyeth, LLC.
    Inventors: John Wozney, Howard Seeherman, Christopher Todd Brown
  • Patent number: 10336813
    Abstract: Disclosed is a fusion protein Slit2D2-HSA formed by fusion of a Slit2D2 polypeptide and a human serum albumin HSA, and use thereof for the manufacture of a medicament for prophylaxis and/or treatment of sepsis, and the said fusion protein Slit2D2-HSA retains the pharmacological activities of Slit2 in inhibition of neutrophil migration and treatment of sepsis, and has an improved stability, prolonged half-life and improved therapeutic effect of sepsis. Compared with protein of Slit2, the polypeptide of Slit2D2 has a smaller molecular weight which is much easier to be purified and separated in preparation and used in the development of drugs.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: July 2, 2019
    Assignee: ASCLEPIUS (SUZHOU) TECHNOLOGY COMPANY GROUP CO., LTD.
    Inventor: Huashun Li
  • Patent number: 10316081
    Abstract: The present disclosure is directed to humanized anti-C1q antibodies and methods of using them.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: June 11, 2019
    Assignee: Annexon, Inc.
    Inventors: Arnon Rosenthal, Michael Leviten
  • Patent number: 10301607
    Abstract: The present invention relates to novel methods of generating and screening for chimeric polypeptides, which can be used in the treatment and prophylaxis of pathogenic bacterial contamination, colonization and infection. The novel methods are based on random recombination of protein domains, and the chimeric polypeptides obtainable by the methods according to the invention are characterized in that they comprise at least one enzymatic active domain (EAD) and at least one cell binding domain (CBD). The present invention also relates to a library of chimeric polypeptides obtainable by the methods of the present invention.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: May 28, 2019
    Assignee: HYPHARM GMBH
    Inventors: Anna Scherzinger, Sonja Molinaro, Bernd Buchberger
  • Patent number: 10273303
    Abstract: Provided herein are monovalent antigen-binding constructs targeting EGFR and/or HER2. The monovalent antigen-binding constructs can include at least one antigen-binding polypeptide comprising a heavy chain variable domain, wherein the antigen-bind polypeptide specifically binds EGFR and/or HER2; and a heterodimeric Fc domain, the Fc domain comprising at least two CH3 domains, wherein the Fc domain is coupled, with or without a linker, to the antigen-binding polypeptide. Also provided are methods of making the constructs and methods of using the constructs.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: April 30, 2019
    Assignee: Zymeworks Inc.
    Inventors: Gordon Yiu Kon Ng, Peter Wing Yiu Chan, Grant Raymond Wickman
  • Patent number: 10208100
    Abstract: In one aspect, provided herein is a polypeptide comprising a modified angiopoietin receptor or fragment thereof, wherein the polypeptide binds preferentially to angiopoietin-2 compared to angiopoietin-1. Nucleic acid sequences encoding the polypeptide, as well as pharmaceutical uses of the polypeptide in treating diseases such as cancer and inflammation are also provided.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: February 19, 2019
    Assignee: UNITED KINGDOM RESEARCH AND INNOVATION
    Inventors: Nicolas Phillip James Brindle, Julian Edward Sale
  • Patent number: 10125197
    Abstract: The invention relates to a cytotoxic modular antibody with a molecular weight of up to 60 kD, specifically binding to a cell surface target with a binding affinity of Kd<10?8 M, a method of producing such antibody and its use as a therapeutic.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: November 13, 2018
    Assignee: F-STAR BIOTECHNOLOGISCHE FORSCHUNGS-UND ENTWICKLUNGSGES.M.B.H
    Inventors: Gottfried Himmler, Geert Mudde, Anton Bauer, Gerda Redl, Maximillian Woisetschlager
  • Patent number: 10087227
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: October 2, 2018
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Xiaoting Wang
  • Patent number: 10080785
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: September 25, 2018
    Assignee: NOVOZYMES BIOPHARMA DK A/S
    Inventors: David J. Ballance, Darrell Sleep, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
  • Patent number: 10077290
    Abstract: Internally cross-linked peptides useful for interfering with Respiratory Syncytial Virus (RSV) infection is based on RSV-F protein. These peptides are capable of reducing infection in cellular and animal models.
    Type: Grant
    Filed: December 31, 2012
    Date of Patent: September 18, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Loren D. Walensky, Gregory H. Bird
  • Patent number: 10017555
    Abstract: The present invention provides an anthropogenic glucagon-like peptide-1 (GLP-1) recombinant protein molecule fused with an anthropogenic immunoglobulin subtype (IgG2) Fc section and a preparation method and purpose thereof. The fusion protein has the biological activity of GLP-1, and also has a significantly prolonged half-life in vivo. The fusion protein can be used to treat type II diabetes, obesity, and other diseases that are treated by decreasing serum glucose, suppressing gastrointestinal motility, and emptying or suppressing food intake.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: July 10, 2018
    Assignee: Genor Biopharma Co., Ltd
    Inventors: Joe Zhou, Qing Zhou, Rulei Chen, Shu Shi, Weihong Nian, Hongbin Yan
  • Patent number: 9908918
    Abstract: Engineered orange-red fluorescent proteins with enhanced fluorescent properties, obtained by mutagenesis of mNeptune2, are disclosed. In particular, the invention relates to engineered orange-red fluorescent proteins excitable with cyan light having increased emission intensity and their use in bioluminescent resonance energy transfer systems and fluorescence and bioluminescence imaging.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: March 6, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Michael Lin, Jun Chu, Younghee Oh
  • Patent number: 9856311
    Abstract: Libraries of immunoglobulins which each have one or more amino acid modifications in at least one structural loop region of such immunoglobulins, where the modified loop region specifically binds to an epitope of an antigen to which an unmodified immunoglobulin does not significantly bind.
    Type: Grant
    Filed: May 31, 2011
    Date of Patent: January 2, 2018
    Assignee: F-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H
    Inventors: Florian Ruker, Gottfried Himmler, Gordana Wozniak-Knopp
  • Patent number: 9850289
    Abstract: The present invention is generally directed to fusion proteins containing a targeting sequence that targets the fusion protein to the exosporium of a Bacillus cereus family member. The invention also relates to recombinant Bacillus cereus family members expressing such fusion proteins and formulations containing the recombinant Bacillus cereus family members expressing the fusion proteins. Methods for stimulating plant growth, for protecting plants from pathogens, and for enhancing stress resistance in a plant by applying the recombinant Bacillus cereus family members or the formulations to plants or a plant growth medium are also described. The invention also relates to methods for immobilizing spores of a recombinant Bacillus cereus family member expressing a fusion protein on plants.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: December 26, 2017
    Assignee: Spogen Biotech Inc.
    Inventors: Brian Thompson, Katie Thompson
  • Patent number: 9821039
    Abstract: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acid vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: November 21, 2017
    Assignee: ALBUMEDIX A/S
    Inventors: David J. Ballance, Darrell Sleep
  • Patent number: 9815880
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: November 14, 2017
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Xiaoting Wang
  • Patent number: 9771556
    Abstract: Vitronectin-derived cell culture substrates and methods of using the same for culturing pluripotent stem cells are presented. Also provided herein are defined culture systems for maintaining human pluripotent stem cells in a substantially undifferentiated state, where the defined culture system comprises human pluripotent stem cells, a defined culture medium, and at least one polypeptide selected from the group consisting of residues 43 to 378 of SEQ ID NO:1 and residues 45 to 378 of SEQ ID NO:1, and where the defined culture medium comprises insulin, selenium, transferrin, L-ascorbic acid, FGF2, DMEM/F12, NaHCO3, and one of TGF? and NODAL.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: September 26, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: James A. Thomson, Zhonggang Hou, Guokai Chen
  • Patent number: 9757470
    Abstract: The present invention provides compositions and methods useful for delivering agents to target cells or tissues, for example nerve cells and other cells in the central nervous system. The compositions and methods are useful for delivering agents across the blood-brain barrier. The present invention also provides methods of using the compositions provided by the present invention to deliver agents, for example therapeutic agents for the treatment of neurologically related disorders.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: September 12, 2017
    Assignee: Children's Medical Center Corporation
    Inventors: Manjunath Narasimhaswamy, Premlata Shankar, Priti Kumar
  • Patent number: 9701970
    Abstract: The present invention relates to isolated promoters and constructs, vectors, and fungal host cells comprising such promoters operably linked to polynucleotides encoding polypeptides. The present invention also relates to methods for producing such polypeptides.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: July 11, 2017
    Assignee: Novozymes, Inc.
    Inventors: Sandra Merino, Debbie Yaver
  • Patent number: 9696316
    Abstract: Disclosed are novel peptides that are useful, for example, for detecting target proteins having a ?-sheet secondary structure which may be associated with a disease, and for diagnosing and treating such a disease. Related methods and kits also are disclosed.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: July 4, 2017
    Assignee: SYSTEM OF SYSTEMS ANALYTICS, INC.
    Inventors: D. Roxanne Duan, Jonathan R. Moll, Alan Rudolph, Renee Wegrzyn
  • Patent number: 9689005
    Abstract: The present invention relates to a recombinant eukaryotic cell selected from a yeast of a filamentous fungus comprising a nucleotide sequence encoding a NAD(H)-dependent fumarate reductase that catalyzes the conversion of fumaric acid to succinic acid. The invention further relates to a process for the production of succinic acid wherein the eukaryotic cell according to the present invention is used.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: June 27, 2017
    Assignee: DSM IP ASSETS B.V.
    Inventors: Rene Verwaal, Liang Wu, Robbertus Antonius Damveld, Cornelis Maria Jacobus Sagt
  • Patent number: 9689014
    Abstract: The present disclosure provides a method to express and purify polypeptides and proteins. In the present disclosure the use of lysozyme as a fusion partner is disclosed. Furthermore, purification methods to isolate lysozyme-tagged polypeptides and proteins via lysozyme-specific antibodies are described. More specifically, the present disclosure provides a method to express and purify monomeric polypeptides and proteins by using lysozyme as a tag.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: June 27, 2017
    Assignee: MORPHOSYS AG
    Inventors: Stefan Haertle, Sebastian Jaeger, Daniela Daubert
  • Patent number: 9670273
    Abstract: The present application discloses humanized 1H7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of Lewy body disease.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: June 6, 2017
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Jose Saldanha, Tarlochan S. Nijjar
  • Patent number: 9657323
    Abstract: A polypeptide cleavage method characterized in that arginine or lysine is at the P1 position of a desired cleavage site in a polypeptide, an amino acid other than aspartic acid, glutamic acid or proline is at the P1? position, a single basic amino acid or two or three consecutive basic amino acids are situated at any site in the amino acid sequence from the P10 position to the P3 position or from the P3? position to the P5? position (with the proviso that a single basic amino acid is not situated at the P6 or P4 position), and OmpT protease or its variant enzyme having a substitution at the 97th amino acid from the N-terminus is used to cleave the desired cleavage site in the polypeptide.
    Type: Grant
    Filed: September 29, 2004
    Date of Patent: May 23, 2017
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kazuaki Okuno, Masayuki Yabuta
  • Patent number: 9650622
    Abstract: The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragm assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: May 16, 2017
    Assignee: Ipsen Bioinnovation Limited
    Inventors: Andreas Rummel, Tanja Weil, Aleksandrs Gutcaits
  • Patent number: 9651559
    Abstract: The present application relates to a method of preparing a genetic package displaying oligomers of modular antibody domains binding to a target and to a scaffold ligand as well as to vectors and libraries of genetic packages produced thereby. The invention further relates to methods of selecting suitable linker sequences for use in such oligomer display.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: May 16, 2017
    Assignee: F-star Biotechnologische Forschungs— und Entwicklungsges.m.b.H
    Inventors: Gottfried Himmler, Geert Mudde, Gerda Redl, Florian Ruker, Gordana Wozniak-Knopp
  • Patent number: 9637753
    Abstract: The present invention encompasses a method for the production of Apolipoproteins in dimeric and/or oligomeric forms (comprising three or more units) of muteins of the human ApoA-1 protein in plant seeds, novel variants of these proteins having an increased stability and capacity to transport cholesterol compared to the native ApoA-1 protein, expression systems for the production thereof, plants transformed capable of producing said proteins in seeds in dimeric and/or oligomeric forms, and nutraceutical derivatives of these plants.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: May 2, 2017
    Assignee: PLANTECHNO S.R.L.
    Inventors: Corrado Fogher, Serena Reggi, Kiril Perfanov
  • Patent number: 9618516
    Abstract: Disclosed are methods for detecting and quantitatively measuring a binding property of a compound to a target macromolecule, wherein the target macromolecule is subject to denaturation and is linked to a labeling peptide, such as a short enzyme fragment. The method uses a fluid mixture comprising (i) a chimeric molecule comprising a target macromolecule linked to the labeling peptide and (ii) a compound being measured for binding to the target macromolecule, wherein said target macromolecule is subject to denaturation. After allowing for binding of the compound (e.g. a small molecule inhibitor of the target macromolecule), one detects a signal from the labeling peptide, such as by enzyme fragment complementation. This signal indicates a differential between denatured and non-denatured target macromolecules and thereby indicates a differential between target macromolecules not bound to the compound and target macromolecules bound to the compound, respectively.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: April 11, 2017
    Assignee: DISCOVERX CORPORATION
    Inventors: Daniel K. Treiber, Elena Menichelli
  • Patent number: 9593157
    Abstract: Described are polypeptides and their use for screening and drug discovery. More specifically, the disclosure provides chimeric polypeptides comprising a membrane protein, in particular a GPCR, fused to a binding domain, wherein the binding domain is directed against and/or specifically binds to the membrane protein. In particular, the chimeric polypeptides are single proteins wherein, in an intramolecular reaction, the binding domain stabilizes the membrane protein in a conformation of interest. Also provided are nucleic acid sequences encoding such chimeric polypeptides, cells capable of expressing such chimeric polypeptides as well as cellular compositions derived thereof. Also screening methods for compounds using the chimeric polypeptides.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: March 14, 2017
    Assignees: VIB VZW, Vrije Universiteit Brussel
    Inventors: Jan Steyaert, Toon Laeremans, Els Pardon
  • Patent number: 9579273
    Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. In these methods, the therapeutic agent is not a PTH/PTHrP receptor agonist or antagonist, basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF). The bacterial collagen-binding polypeptide segment delivers the agent to sites of partially untwisted or under-twisted collagen. Methods of treating collagenopathies using a composition including a collagen-binding polypeptide and a PTH/PTHrP receptor agonist are also provided. In addition, methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. Finally, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: February 28, 2017
    Assignees: The Kitasato Institute, National University Corporation Kagawa University
    Inventors: Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure, Nozomu Nishi
  • Patent number: 9573980
    Abstract: The present invention is generally directed to fusion proteins containing a targeting sequence that targets the fusion protein to the exosporium of a Bacillus cereus family member. The invention also relates to recombinant Bacillus cereus family members expressing such fusion proteins, formulations containing the recombinant Bacillus cereus family members expressing the fusion proteins. Methods for stimulating plant growth and for protecting plants from pathogens by applying the recombinant Bacillus cereus family members or the formulations to plants or a plant growth medium are also described. The invention also relates to methods for immobilizing spores of a recombinant Bacillus cereus family member expressing a fusion protein on plant roots.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 21, 2017
    Assignee: Spogen Biotech Inc.
    Inventors: Brian Thompson, Katie Thompson
  • Patent number: 9562086
    Abstract: Isolated protein complexes are provided comprising keratinocyte growth factor and vitronectin, or at least domains thereof that enable binding to and activation of both a keratinocyte growth factor receptor and an integrin receptor for vitronectin. These protein complexes include synthetic proteins where the keratinocyte growth factor and vitronectin sequences are joined by a linker sequence. In particular forms, vitronectin sequences do not include a C-terminal heparin binding domain. Also provided are uses of these protein complexes for stimulating or inducing cell migration and/or proliferation in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement, skin replenishment and treatment of burns where epithelial cell migration is required. In other embodiments, the invention provides inhibition of cancer cell metastasis, particularly in relation to breast cancer.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: February 7, 2017
    Assignee: QUEENSLAND UNIVERSITY OF TECHNOLOGY
    Inventor: Zee Upton
  • Patent number: 9533026
    Abstract: In certain embodiments, this present invention provides polypeptide compositions, including compositions containing a modified polypeptide, and methods for inhibiting Ephrin B2 or EphB4 activity. In other embodiments, the present invention provides methods and compositions for treating cancer or for treating angiogenesis-associated diseases.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: January 3, 2017
    Assignee: VASGENE THERAPEUTICS, INC
    Inventors: Valery Krasnoperov, Nathalie Kertesz, Ramachandra Reddy, Parkash Gill, Sergey Zozulya
  • Patent number: 9505821
    Abstract: Disclosed herein are nucleic acid sequences that encode pro-apoptotic polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of proliferative disorders and bacterial infections using the nucleic acids and proteins of the invention.
    Type: Grant
    Filed: October 3, 2007
    Date of Patent: November 29, 2016
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Jianjie Ma, Jae-Kyun Ko, Chul-Woo Kim, Noah Weisleder
  • Patent number: 9493531
    Abstract: This application is directed to chemokine-immunoglobulin fusion polypeptides and chemokine-polymer conjugates. The fusion polypeptides and conjugates can be used for treating chemokine receptor-mediated disorders and modulating inflammation, inflammatory cell motility, cancer cell motility, or cancer cell survival.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: November 15, 2016
    Assignee: JYANT TECHNOLOGIES, INC.
    Inventor: James W. Lillard, Jr.
  • Patent number: 9487575
    Abstract: Molecules and compositions that can be used in the treatment of gynecologic cancers are described. ApoA-1, in particular, is demonstrated to inhibit the proliferation of cancer cells reduce tumor size in a mouse model of ovarian cancer.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: November 8, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Robin Farias-Eisner, Srinivasa T. Reddy
  • Patent number: 9480743
    Abstract: The present invention is related to a pharmaceutical formulation comprising a biopharmaceutical drug, said composition further comprising at least one mono- or dicarboxylic acid with a backbone of 2-6 C-Atoms, or at least one salt thereof.
    Type: Grant
    Filed: December 28, 2011
    Date of Patent: November 1, 2016
    Assignee: Hexal AG
    Inventors: Martina Danek-Bulius, Britta Deutel, Sabine Fürtinger, Bernt Pragl, Drago Kuzman
  • Patent number: 9447434
    Abstract: Gene targeting is a technique to introduce genetic change into one or more specific locations in the genome of a cell. For example, gene targeting can introduce genetic change by modifying, repairing, attenuating or inactivating a target gene or other chromosomal DNA. In one aspect, this disclosure relates to methods and compositions for gene targeting with high efficiency in a cell. This disclosure also relates to methods of treating or preventing a genetic disease in an individual in need thereof. Further disclosed are chimeric nucleases and vectors encoding chimeric nucleases.
    Type: Grant
    Filed: September 5, 2003
    Date of Patent: September 20, 2016
    Assignee: California Institute of Technology
    Inventors: David Baltimore, Matthew Porteus
  • Patent number: 9439980
    Abstract: The application relates to a composition comprising: a stably integrating delivery vector; a modified mammalian thymidylate kinase (tmpk) wherein the modified mammalian tmpk increases phosphorylation of a prodrug relative to phosophorylation of the prodrug by wild-type human tmpk; and a detection cassette fused to tmpk. The application also relates to use of these compositions in methods of treatment of diseases such as graft versus host disease and cancer.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: September 13, 2016
    Assignee: Univeristy Health Network
    Inventors: Jeffrey A. Medin, Sean Devine
  • Patent number: 9428571
    Abstract: Provided herein are various processes for the improved production of antibody producing organisms, antibody producing tissues, antibody producing cells and antibodies. In certain embodiments, provided herein are methods for rapidly producing antibody producing organisms, tissues, cells and antibodies derived from humans, organisms, plants or cells that are genetically altered to over-express certain proteins.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: August 30, 2016
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Yosef Refaeli, Brian Turner
  • Patent number: 9409942
    Abstract: The current invention provides methods for producing a polypeptide as inclusion bodies in bacterial host cells. The present methods are carried out by forming a gene construct comprising the genetic sequence encoding a polypeptide operatively linked to that of an inclusion partner protein, such that host cells comprising the gene construct produce the polypeptide as intracellular inclusion bodies thereby facilitating rapid isolation and purification of recombinant proteins. The invention further provides methods for producing protein molecular weight ladders for us in protein gel electrophoresis, as well as proteins and protein molecular weight ladders produced by these methods.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: August 9, 2016
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: Deb Chatterjee, Mary Longo, Elizabeth Flynn, Robert Oberfelder
  • Patent number: 9394534
    Abstract: The present invention relates to polypeptides comprising a enzymatically non-active cell wall binding domain of an endolysin or another cell wall lysing enzyme, and a sequence according to SEQ ID NO: 1 or derivatives thereof, wherein the polypeptide besides the cell wall binding domain comprises no further domains of an endolysin, as well as means for their preparation. The present invention further relates to methods for binding, enriching, removing from a sample, capturing and/or detecting bacteria, particularly gram positive bacteria.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: July 19, 2016
    Assignee: BIOMERIEUX S.A.
    Inventors: Martina Beissinger, Stefan Miller, Anja Philipp, Michael Schütz
  • Patent number: 9376686
    Abstract: The present invention relates to a new vaccine delivery system. In particular, the present invention includes compositions and methods of integrally transformed non-pathogenic, commensal bacteria that can express a nucleic acid molecule of a foreign polypeptide, wherein the nucleic acid molecule that encodes the foreign polypeptide is stably integrated into genomic DNA of the bacteria. The foreign polypeptide includes a vaccine antigen that elicits an immunogenic response, an inhibitor of a pathogen, or an immune booster or modulator.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: June 28, 2016
    Assignee: Forsyth Dental Infirmary for Children
    Inventors: Antonio Campos-Neto, Mark Cayabyab, Margaret Duncan
  • Patent number: RE47528
    Abstract: We have identified by molecular cloning a protease which originates from the larvae of Lucilia sericata and which was termed debrilase due to its activities useful for debridement of wounds.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: July 23, 2019
    Assignee: B.R.A.I.N. BIOTECHNOLOGY RESEARCH AND INFORMATION NETWORK AG
    Inventors: Frank Niehaus, Jürgen Eck, Renate Schulze, Michael Krohn